<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q/A
AMENDMENT NO. 2
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1996
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ________ to ________
Commission File Number 0-22788
ARRIS PHARMACEUTICAL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 22-2969941
- --------------------------------------------------------------------------------
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)
385 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CALIFORNIA 94080
(Address of principal executive offices including zip code)
(415) 829-1000
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. [X] Yes [ ] No.
The number of outstanding shares of the registrant's Common Stock, $0.001 par
value, was 13,992,805 as of April 30, 1996.
<PAGE>
ARRIS PHARMACEUTICAL CORPORATION
INDEX
PAGE NUMBER
-----------
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K. 3
SIGNATURES 4
2
<PAGE>
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K.
(a) Exhibits
Item Description
---- -----------
10.33* Amendment to Agreement dated March 29, 1993 between the
Registrant and Kabi Pharmacia AB, dated January 31,
1996. (1)
10.34* First Amendment to Research and License Agreement dated
May 28, 1993 between Registrant and Amgen, Inc., dated
February 2, 1996. (1)
10.35 Research Agreement between the Registrant and Pharmacia
& Upjohn, Inc., a Delaware corporation, dated February
29, 1996. (1)(2)
10.36* Form of Sixth Amendment to Lease dated October 15, 1992
between the Registrant and Shelton Properties, Inc.
dated March 27, 1996.
10.37* Financing Agreement between Hambrecht and Quist
Guaranty Finance, LLC, dated March 29, 1996, including
Security Agreement and Warrant Purchase Agreement of
even date.
10.38* Amendment to Lease Schedule under Master Property Lease
Agreement dated March 29, 1994 between Hambrecht and
Quist Guaranty Finance, L.P., dated March 29, 1996.
27* Financial Data Schedule
* Previously filed
(1) Confidential treatment has been requested for portions to this document.
Brackets indicate portions of text that have been omitted. A separate filing of
such omitted text has been made with the Commission as part of the Company's
application for confidential treatment.
(2) Appendix A, the Collaboration Agreement between Registrant and Pharmacia AB,
dated March 29, 1993, is incorporated herein by reference to Exhibit 10.15 to
Amendment No. 1 of the Registrant's Registration Statement on Form S-1 filed
October 13, 1993 and Exhibit 10.15(a) to Amendment No. 3 of the Registrant's
Registration Statement on Form S-1 filed November 17, 1993. Appendix B, the
Research Agreement between Registrant and Pharmacia AB, dated December 21, 1994,
is incorporated herein by reference to Exhibit 10.25 to the Registrant's Annual
Report on Form 10-K for the fiscal year ended December 31, 1994.
(b) Reports on Form 8-K
A Current Report on Form 8-K was filed on January 5, 1996, as
amended on February 5, 1996 to include financial statements and pro
forma financial information, in conjunction with the Company's
acquisition of Khepri Pharmaceuticals, Inc., which was completed on
December 22, 1995.
3
<PAGE>
ARRIS PHARMACEUTICAL CORPORATION
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed in its behalf by the
undersigned thereunto duly authorized.
ARRIS PHARMACEUTICAL CORPORATION
Date: August 23, 1996 By: /s/ John P. Walker
--------------------------------------
John P. Walker
President, Chief Executive Officer
and Director
Date: August 23, 1996 By: /s/ Daniel H. Petree
--------------------------------------
Daniel H. Petree
Executive Vice President, Corporate
Development, and Chief Financial Officer
4
<PAGE>
ARRIS PHARMACEUTICAL CORPORATION
INDEX OF EXHIBITS
10.33* Amendment to Agreement dated March 29, 1993 between the
Registrant and Kabi Pharmacia AB, dated January 31,
1996. (1)
10.34* First Amendment to Research and License Agreement dated
May 28, 1993 between Registrant and Amgen, Inc., dated
February 2, 1996. (1)
10.35 Research Agreement between the Registrant and Pharmacia
& Upjohn, Inc., a Delaware corporation, dated February
29, 1996. (1)(2)
10.36* Form of Sixth Amendment to Lease dated October 15, 1992
between the Registrant and Shelton Properties, Inc.
dated March 27, 1996.
10.37* Financing Agreement between Hambrecht and Quist
Guaranty Finance, LLC, dated March 29, 1996, including
Security Agreement and Warrant Purchase Agreement of
even date.
10.38* Amendment to Lease Schedule under Master Property Lease
Agreement dated March 29, 1994 between Hambrecht and
Quist Guaranty Finance, L.P., dated March 29, 1996.
27* Financial Data Schedule
* Previously filed
(1) Confidential treatment has been requested for portions to this document.
Brackets indicate portions of text that have been omitted. A separate filing of
such omitted text has been made with the Commission as part of the Company's
application for confidential treatment.
(2) Appendix A, the Collaboration Agreement between Registrant and Pharmacia AB,
dated March 29, 1993, is incorporated herein by reference to Exhibit 10.15 to
Amendment No. 1 of the Registrant's Registration Statement on Form S-1 filed
October 13, 1993 and Exhibit 10.15(a) to Amendment No. 3 of the Registrant's
Registration Statement on Form S-1 filed November 17, 1993. Appendix B, the
Research Agreement between Registrant and Pharmacia AB, dated December 21, 1994,
is incorporated herein by reference to Exhibit 10.25 to the Registrant's Annual
Report on Form 10-K for the fiscal year ended December 31, 1994.
5
<PAGE>
EXHIBIT 10.35
Arris/P&U Research Agreement
RESEARCH AGREEMENT
This Research Agreement (the "Agreement") is made and entered into as of this
29th day of February, 1996 (hereinafter, "Effective Date") by and between
Pharmacia & Upjohn, Inc. a Delaware Corporation having a place of business at
7000 Portage Road, Portage, Michigan 49001, (hereinafter, "P&U") and Arris
Pharmaceutical Corporation, 385 Oyster Point Boulevard, Suite 3, South San
Francisco, CA 94080, a Delaware corporation (hereinafter, "Arris").
WHEREAS, Arris and Kabi Pharmacia AB previously entered into a Collaboration
Agreement dated March 29, 1993 (hereinafter, "Collaboration Agreement"
attached as Appendix "A"), pursuant to which they are conducting a research
collaboration seeking to identify one or more orally active mimics of or
antagonists to human growth hormone and [***] and a Collaborative Research and
License Agreement dated August 29, 1995, (hereinafter, "Collaborative
Agreement") directed toward discovering compositions having anti-coagulation
activity targeting enzyme factor Xa, enzyme factor VIIa or the enzyme
Thrombin.
WHEREAS, Arris and Pharmacia AB previously entered into a Research Agreement
dated December 21, 1994 (hereinafter, "Research Agreement" attached as Appendix
"B"), pursuant to which the parties are conducting a research collaboration to
utilize combinatorial chemistry and high throughput screening (EMS) to
facilitate Pharmacia's drug discovery efforts.
WHEREAS, P&U is the merged company formed by the merger of Pharmacia AB and The
Upjohn Company, and P&U desires to continue the Research Agreement for the
collaboration with Arris to utilize combinatorial chemistry for P&U drug
discovery efforts.
NOW THEREFORE, in consideration of the mutual covenants and promises contained
herein, the parties do hereby agree as follows:
DEFINITIONS
Unless otherwise provided herein, all definitions will be as provided in the
Collaboration Agreement.
[***] Confidential Treatment Requested
<PAGE>
Arris/P&U Research Agreement
"Library" means those compounds prepared by Arris under this Agreement which
includes the set of 250,000 suitably dissimilar nonpeptide compounds using
combinatorial chemistry techniques (also hereinafter referred to as the
"Diversity Set") and the 90,000 compounds supplied by Arris under the Research
Agreement ( also hereinafter referred to as the "Research Agreement Set").
1. DUTIES
1.1 Arris agrees to develop and provide P&U with the following:
(a) Scientific tools, know-how and expertise for establishing
combinatorial chemistry library synthesis capability at P&U's
facilities worldwide including those in the U.S.A., Italy and Sweden
using compatible, if not identical, hardware and software.
(b) A set of 250,000 suitably dissimilar nonpeptide compounds prepared by
Arris using combinatorial chemistry techniques (hereinafter,
"Diversity Set"). The Diversity Set will be prepared and delivered to
P&U on an ongoing basis in a format specified by P&U and acceptable
to Arris at a rate of approximately [***] compounds during the first
year, [***] compounds during the second year and [***] compounds
during the third year of the term of this Agreement. The Diversity
Set will not contain compounds purchased by Arris from third parties,
will be compounds of known structure with accompanying synthesis
protocols and structures in computer readable form, will be
distributed one compound per screening plate well and will be
supplied in a minimum amount of 5 mg to about 10 mg of the compound
in the dry state.
(c) Of the 90,000 compounds to be provided by Arris in the Research
Agreement Set those compounds not yet provided by Arris under the
Research Agreement hereinafter, "Research Agreement Residual Set"),
will be identified as such and will be supplied according to the
schedule in the Research Agreement and as further specified by P&U.
(d) P&U will have access to any Arris Artificial Intelligence,
computational chemistry or other computer technology specifically
designed for lead generation, molecular docking, DE NOVO design,
scaffold selection, library design or chemical diversity developed by
Arris
[***] Confidential Treatment Requested
2
<PAGE>
Arris/P&U Research Agreement
prior to and during the term of this Agreement ("Combichem AI"). Arris
will provide to P&U the code and executables for that software
including that for molecular docking and DE NOVO molecular design.
P&U may from time to time participate with Arris in the joint design
of new software. New software so jointly designed will be jointly
owned by the parties. P&U will share with Arris software developments
including code and executables derived from Combichem AI under this
Agreement.
(e) For the term of this Agreement, Arris will provide to P&U scientific
tools and know-how for high throughput screening (HTS) as previously
provided under the Research Agreement.
(f) [***]
1.2 (a) In carrying out its duties under this Agreement, Arris will annually
devote the efforts of at least [***] FTE's (Full Time Equivalents) of
its fully trained staff to fulfilling its obligations under this
Agreement. These efforts are in addition to those being carried out
and already paid for under the Research Agreement.
(b) Arris will provide to the Research Committee a time report and a
financial accounting on at least a quarterly basis of the FTE's that
are committed under this Agreement and a progress report on at least
a quarterly basis as to the completion of their obligations
[***] Confidential Treatment Requested
3
<PAGE>
Arris/P&U Research Agreement
under this Agreement.
1.3 The set of compounds provided under the Collaboration Agreement, The
Diversity Set and the Research Agreement Set will be mutually exclusive
sets, i.e. no compound in one set will be included in either of the other
sets. The terms of this Agreement will apply to any compound provided
under this Agreement and the Research Agreement.
1.4 If desired by P&U and acceptable to Arris, [***] at a cost to be
determined and agreed upon by the parties in a separate agreement.
2. RESEARCH COMMITTEE
2.1 For the term of this Agreement and [***] thereafter, the parties agree to
form a Research Committee consisting of two representatives from Arris and
up to six representatives from P&U, one of the P&U representatives being
the chair of the Research Committee, to facilitate the research,
collaboration and information exchange contemplated by this Agreement.
2.2 During the term of this Agreement, the Research Committee shall meet
regularly either in person or by tele-conference or video-conference but
at least once every four (4) months. All decisions by the Research
Committee will be made at any of its scheduled meetings and require
agreement by the senior representative of each party present at the
meeting.
2.3 The Research Committee shall be the primary vehicle for formal interaction
between the parties with respect to coordinating the P 1 HE'S obligated
under this Agreement and the research and disclosure of information as
well as transfer of compounds under this Agreement. Without limiting the
foregoing, the Research Committee will be responsible for (a) the timing
and manner of research, disclosure of information, technical exchanges,
transfer of compounds, scientific visits at Arris facilities; (b)
recommending what patent applications should be filed under this Agreement
and reviewing such patent application filings; (c) monitoring the progress
of research and other activities under this Agreement; (d) monitoring and
making
[***] Confidential Treatment Requested
4
<PAGE>
Arris/P&U Research Agreement
decisions under Articles 6.2 and 6.3; (e) the chemical design and
monitoring the delivery of the Diversity Set and the Research Agreement
Residual Set; (f) determining the quality standards, suitability and
acceptability of the purity, diversity and dissimilarity of the compounds
provided under Articles l.l(b) and (c), above; (g) determining the
frequency, time and place of Research Committee meetings.
3. EXCHANGE OF CONFIDENTIAL INFORMATION
3.1 All information generated and relating to the compounds in the Diversity
Set and the Research Agreement Set as well as this Agreement is
confidential information and will not be communicated by P&U or Arris to
any third parties during the term of this Agreement and for [***]
thereafter without the express written consent of the nondisclosing party,
such consent to not be unreasonably withheld. Confidential information
will not include information which:
(a) is already known to the receiving party as evidenced by their own
written records;
(b) is disclosed to the receiving party by a third party who has the right
to make such disclosure;
(c) is or becomes part of the public domain through no fault of the
receiving party;
(d) is required to be disclosed to a government agency anywhere in the
world for legitimate commercial or legal purposes, relating TO, INTER
ALIA, drug registration, marketing, and patent applications; provided
the party required to make any such disclosure first notifies the
other party, allowing for comment prior to disclosure, and makes a
reasonable effort to maintain the confidentiality of such agreement;
or
(e) is disclosed to a collaborator or consultant or collaborator as
permitted under Articles 6.2 and 6.3 of the receiving party for
purposes of carrying out the obligations of this Agreement under a
duty of confidentiality to the disclosing party.
[***] Confidential Treatment Requested
5
<PAGE>
Arris/P&U Research Agreement
3.2 Software which is jointly designed under this Agreement will be
confidential, and its disclosure will be according to the confidentiality
provisions of 3.1, above. Software which is the sole property of either
party will not be disclosed by the receiving party for a period of [***]
after the termination of this Agreement.
4. INVENTIONS AND PATENTS
4.1 Each party is responsible for filing and prosecuting its own patent
applications and maintaining patents issued from such applications for its
inventions under this Agreement as hereinafter provided. In accordance
with applicable laws of inventorship, each party shall cooperate with the
other to obtain such patent rights. [***] will retain title to
inventions, patents, and other intellectual property rights and know-how
which result from its research and development performed under this
Agreement.
4.2 After consultation with the Research Committee, each party responsible for
filing a patent application shall determine its patent filing strategy,
and the other party will cooperate to the extent necessary to prepare all
papers and documentation in the event of jointly invented inventions made
under this Agreement. All costs for such filing, prosecuting, and
maintaining of joint-inventorship patents shall be borne by [***].
4.3 As regards to patentable inventions independently owned by Arris which
cover the Library, [***]. In the event Arris decides to abandon any such
patent [***]. This paragraph will apply MUTATIS MUTANDIS for patentable
inventions independently owned by P&U which are licensed to Arris under
Article 6 of this Agreement.
4.4 Each party shall promptly advise the other upon becoming aware of any
third party infringement of a patent filed under this Agreement. Each
party shall [***] as follows:
(a) [***]
6
<PAGE>
Arris/P&U Research Agreement
[***]
(b) If one party holds exclusive rights to a compound which is the
subject of an infringement, that party [***]. In such event, the other
party shall cooperate fully with [***]. If [***] makes a preliminary
determination not to commence a suit, it shall consult with the other
party on a timely basis regarding such preliminary decision, and shall
consider any arguments made by such other party in favor of commencing
litigation, but the decision whether to institute suit shall remain
with the party holding the exclusive rights.
(c) If the subject of an infringement is not a compound as to which
either party holds exclusive rights, then the parties shall first
consult regarding their preferred course of action, as provided in
paragraph (a), above, and in the absence of agreement to institute
suit jointly, each party shall make its own determination as to what
action is in its best interests for the enforcement of its own
intellectual property rights.
(d) Neither party shall enter into any settlement or compromise which
would in any manner alter, diminish or be in derogation of the other
party's rights under this Agreement without the prior written
consent of such other party.
4.5 If any third party brings suits against either party asserting any patent
infringement related to compound(s) discovered, generated or developed
under this Agreement, [***].
5. PAYMENT
5.1 As partial compensation for services rendered and for the licenses and
grants under Article 6
[***] Confidential Treatment Requested
7
<PAGE>
Arris/P&U Research Agreement
of this Agreement, P&U agrees to pay Arris as follows:
(a) [***] within thirty (30) days of the Effective Date of this Agreement;
(b) [***] by or upon the one (1) year anniversary of the Effective Date of
this Agreement; and
(c) [***] by or upon the second (2) year anniversary of the Effective Date
of this Agreement.
5.2 In addition to the payments under 5.1, above, P&U agrees to pay Arris as
full compensation for the delivery of compounds in the Diversity Set and for the
licenses and grants under Article 6 the following payments. At the end of each
calendar quarter, Arris shall send P&U an invoice for the number of compounds in
the Diversity Set which have been delivered to P&U in such quarter, multiplied
by [***] per compound. In addition, after Arris has delivered the 250,000
compounds to P&U, it shall be due a one-time supplemental fee of [***]. Such
invoices shall be paid by P&U within thirty (30) days after receipt. The
aggregate payments to be made by P&U under this Article 5.2, assuming delivery
by Arris of the full 250,000 compounds in the Diversity Set, shall be [***]
(consisting of [***] per compound delivered plus the one-time supplemental fee
of [***]).
6. OWNERSHIP, GRANTS AND LICENSES
6.1 (a) Subject to l.l(d), regarding [***] each party will [***] during the
term of this Agreement. The compounds and their chemical structures
contained within the Library shall be [***] for the term of this
Agreement and thereafter, subject to the rights exercised under
Articles 6.2 and 6.3.
[***] Confidential Treatment Requested
8
<PAGE>
Arris/P&U Research Agreement
(b) Arris hereby grants to P&U and its Affiliates a nonexclusive,
irrevocable, royalty-free worldwide license under patents and
know-how owned or controlled by Arris and developed prior to or
during the term of this Agreements with no right to sublicense, for
[***].
(c) P&U hereby grants to Arris and its Affiliates a nonexclusive,
irrevocable, royalty-free worldwide license for [***] during the term
of this Agreement, for [***] with no right to sublicense.
6.2 (a) For the term of this Agreement, P&U and its Affiliates agree to
[***] subject to the terms and conditions of parts (b), (c)
and (d) below.
(b) For the term of this Agreement and [***] thereafter, P & U and
its Affiliates have the option to [***] by performing the following
steps:
1) notifying the Research Committee [***],
2) notifying the Research Committee [***]; and
3) obtaining the consent of the Research Committee [***]. The
purpose of such review shall be to
[***] Confidential Treatment Requested
9
<PAGE>
Arris/P&U Research Agreement
[***] The Research Committee shall also have the authority to consent
to
[***] based upon a reasonable demonstration of [***].
(c) Arris agrees to grant P&U and its Affiliates a non-exclusive,
royalty-free, irrevocable worldwide license [***], above. [***];
except as provided under part (d), below.
(d) [***]
6.3 (a) Arris agrees to [***]. Over and above said [***], Arris must disclose
to P&U in sufficient detail [***]. Arris does not have the right [***]
during the term of this Agreement and for [***] thereafter.
[***] Confidential Treatment Requested
10
<PAGE>
Arris/P&U Research Agreement
(b) For the term of this Agreement and [***] thereafter Arris and its
Affiliates have the option to [***] by performing the following steps:
1) notifying the Research Committee of [***],
2) notifying the Research Committee that [***]; and
3) obtaining the consent of the Research Committee to [***]. The
purpose of such review shall be to [***]. The Research Committee shall
also have the authority to consent to [***].
(c) P&U agrees to grant Arris and its Affiliates a non-exclusive, royalty-
free, worldwide license [***] above. [***] except as provided under
part (d), below.
(d) [***]
[***] Confidential Treatment Requested
11
<PAGE>
Arris/P&U Research Agreement
[***]
6.4 Under either part 6.2(b) or 6.3(b), above, any [***] will be identified in
writing to the other party and Research Committee and shall represent a
commitment to develop or have developed [***] although no such
notification shall obligate either party [***], and failure to do so [***]
or other proofs satisfactory to the Research Committee will cause [***].
[***], respectively. In the event [***]. If both parties [***].
6.5 For purposes of part 6.2(c) or 6.3(c), Arris patent or know-how or P&U
patent or know-how, respectively shall mean a patent or know-how owned or
controlled by that party or patents or know-how licensed to that party,
and not held jointly with each other; and the term "Affiliates" shall have
the same meaning as defined in the Collaboration Agreement.
6.6 After the term of this Agreement and the [***] thereafter, the [***]. The
licenses set forth in Article 6.1(b) and any exclusive rights which have
been obtained by either party under 62 or 6.3 shall continue for the
periods indicated therein, but otherwise all licenses in this Agreement
shall terminate.
6.7 In the event a third party patent(s) issues or is discovered in the
U.S.A., Europe or Japan which through no fault of either party prevents
the use of the Arris Combichem AI or the use, manufacture or sale of
[***], such that
[***] Confidential Treatment Requested
12
<PAGE>
Arris/P&U Research Agreement
the essential purposes of P&U in entering into this Agreement are
compromised, then the parties shall discuss and renegotiate the terms
and financial obligations of this Agreement to take into consideration
this situation. If agreement cannot be reached or if no license can be
obtained from such third party, through no fault of either party to this
Agreement, (neither party being obligated to institute litigation
against any such third party), then P&U will have the right to terminate
this Agreement without any further obligations or duties to Arris;
except the duty of confidentiality under Article 3 and to the extent
available a right of access to the Library under Article 6.
7. TERM AND TERMINATION
7.1 This Agreement shall be effective as of the date first written above and
shall remain in effect for three (3) years. This Agreement may be extended
upon written agreement by the parties. References in this Agreement to the
period [***] after termination means the period immediately following
termination or conclusion of any extension period.
7.2 Notwithstanding the provisions of Article 7.1 above, either party may
terminate this Agreement upon the bankruptcy or insolvency of the other or
an admission by the other of its inability to pay debts as they become
due.
7.3 P&U has the right to terminate this Agreement under Article 6.7, above.
7.4 This agreement may be terminated by either party for breach or default by
the other party, or for substantial failure by the other party to perform
its duties under this Agreement. If either party is in breach or default
of any of the provisions of this Agreement, or has substantially failed to
perform its duties under this Agreement, and does not rectify such breach
or default or failure within [***] from written notice thereof, the other
party can terminate this Agreement by notice.
7.5 Termination of this Agreement for any reason by either party shall not
relieve the parties of any obligation accruing prior to termination, such
as confidentiality and other provisions which
[***] Confidential Treatment Requested
13
<PAGE>
Arris/P&U Research Agreement
by their nature would survive such termination. Any termination of this
Agreement by either party under this Article 7 shall not constitute an
election of remedies by it, and it shall in addition, have all other
remedies provided by law.
7.6 The right of either party to terminate this Agreement as hereinabove
provided shall not be affected in any way by its waiver of or failure to
take action with respect to any previous default. Any such termination
shall be without prejudice to any further rights and remedies vested in
the parties. The license rights granted herein shall survive the
bankruptcy or reorganization of either party.
8. GENERAL PROVISIONS
8.1 This Agreement controls, modifies and supersedes the Research Agreement to
the extent any provisions between them are inconsistent or redundant. This
Agreement, except as otherwise provided herein, constitutes the entire
understanding between the parties with reference to the subject matter
hereof, and no waiver, modification, or amendment of this Agreement shall
be valid or effective unless made in writing and signed by a duly
authorized officer of each party. Should the Collaboration Agreement be
terminated or expire, the references herein to provisions in the
Collaboration Agreement shall remain valid and effective for the purpose
of this Agreement. This Agreement is otherwise separate and independent
from the Collaboration Agreement and the Collaborative Agreement.
8.2 Neither this Agreement nor any interest hereunder shall be assignable by
either party without the other party's written consent; provided, however,
that a party may assign this agreement to any wholly owned subsidiary or
to any successor by merger or sale or the like of substantially all of its
assets to which this Agreement relates in a manner such that the assignor
shall remain liable and responsible for the performance and observance of
all its duties and obligations hereunder.
8.3 The parties expressly agree and contract that it is not the intention of
either party to violate any public policy, statutory or common laws,
rules, regulation, treaties or decisions of any government or agency
thereof of any country. If any word, sentence, paragraph, clause or
14
<PAGE>
Arris/P&U Research Agreement
combination thereof of this Agreement is judicially or administratively
interpreted or construed as being in violation of any such provisions in
any country, such words, sentences, paragraphs, clauses or combinations
thereof shall be inoperative in each such country and the remainder of
this Agreement shall remain binding upon the parties to this Agreement.
8.4 All notices Squired or authorized to be given under this Agreement shall
be in writing and shall be sent by registered or certified mail,
facsimile, courier, telex or the like to the following addresses for the
respective parties. Such notice shall be effective as of its date of
mailing or transmission.
President
Arris Pharmaceutical Corporation
385 Oyster Point Boulevard, Suite 3
South San Francisco, CA 94080
FAX: 415-737-8590
and
V.P. of Business Development
Pharmacia & Upjohn, Inc.
7000 Portage Road
Portage, Michigan 49001
FAX 616-323-6247
with a copy to
Exec. V P. Worldwide Science and Technology
Pharmacia & Upjohn, Inc.
Knyvett House, The Causeway
Staines
Middlesex TW18 3BA
United Kingdom
15
<PAGE>
8.5 Force Majeure Neither of the undersigned parties shall be liable for
failure to perform its obligations under this Agreement (other than the
payment of monies due) when occasioned by contingencies beyond its
control, such as strikes or other work stoppages, lock-outs, riots, wars
and acts of God, such as fire, floods, storms, and earthquakes. Each
party will notify the other immediately should any such contingency
occur and any time for performance hereunder shall be extended by the
actual time of delay caused by such occurrence.
8.6 (a) No right, expressed or implied, is granted to Arris to use in any
manner the name "Pharmacia AB", "The Upjohn Company" or "Pharmacia &
Upjohn, Inc." or any form thereof or any other trademark or trade
name of P&U or its Affiliates in connection with the performance of
this Agreement. No right, expressed or implied, is granted to P&U to
use in any manner the name "Arris" or any form thereof or any other
trademark or trade name of Arris or its Affiliates in connection
with the performance of this Agreement.
(b) Neither party will issue any press release, SEC filings, prospectus
or any other public announcement relating to this Agreement or its
terms without obtaining the other party's prior written approval
which approval will not be unreasonably withheld. The term "press
release", as used herein, includes follow-up correspondence, press
kits, and the like which may be provided in response to inquiries
from the media or others.
8.7 All titles and captions in this Agreement are for convenience only and
shall not be of any meaning or substance.
8.8 This Agreement may be executed in any number of counterparts, each of
which shall be deemed an original, but all of which together shall
constitute one and the same instrument.
8.9 Each party reserves the right to fulfill its obligations and exercise its
rights under this Agreement through the actions of any of its Affiliates.
8.10 Arris and P&U shall each have the status of an independent contractor
without the power to
16
<PAGE>
Arris/P&U Research Agreement
act as an agent or otherwise bind the other party or its employees.
8.11 This Agreement shall be construed in accordance with and governed by the
laws of the State of Michigan excluding the conflict of laws provisions.
IN WITNESS HEREOF, the parties intending to be bound hereby have caused this
Agreement to be signed by their duly authorized representatives as of the day
and year first above written.
ACCEPTED AND AGREED TO
ARRIS PHARMACEUTICAL CORP. PHARMACIA & UPJOHN, INCORPORATED
/s/Daniel H. Petree /s/ Ley S. Smith
- -------------------------- -----------------------------
Name: Daniel H. Petree Name: Ley S. Smith
Title: V.P., C.F.O. Title: Executive VP & President PPC U.S.
17
<PAGE>
Arris/P&U Research Agreement
APPENDIX A
COLLABORATION AGREEMENT DATED MARCH 29, 1993*
______________
* Appendix A, the Collaboration Agreement between Registrant and Pharmacia
AB, dated March 29, 1993, is incorporated herein by reference to Exhibit 10.15
to Amendment No. 1 of the Registrant's Registration Statement on Form S-1
filed October 13, 1993 and Exhibit 10.15(a) to Amendment No. 3 of the
Registrant's Registration Statement on Form S-1 filed November 17, 1993.
<PAGE>
Arris/P&U Research Agreement
APPENDIX B
RESEARCH AGREEMENT, DATED DECEMBER 21, 1994*
______________
* Appendix B, the Research Agreement between Registrant and Pharmacia
AB, dated December 21, 1994, is incorporated herein by reference to Exhibit
10.25 to the Registrant's Annual Report on Form 10-K for the fiscal year ended
December 31, 1994.
